WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic and Inflammatory Research

Executive Summary: WY-14643 (Pirinixic Acid) is a highly selective peroxisome proliferator-activated receptor alpha (PPARα) agonist with an IC₅₀ of 10.11 µM for human PPARα, facilitating precise modulation of lipid metabolism and inflammation (Bao et al., 2025). Aliphatic α-substitution enhances dual PPARα/γ agonist activity in the low micromolar range. In animal models, oral WY-14643 (3 mg/kg/day, 2 weeks) reduces plasma glucose, triglycerides, and visceral fat while improving whole-body insulin sensitivity. It exhibits anti-inflammatory effects by downregulating VCAM-1 expression and monocyte adhesion upon TNF-α stimulation. WY-14643 is supplied by APExBIO for research use only (APExBIO A4305).

Biological Rationale

Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that regulate gene expression involved in lipid metabolism, inflammation, and energy homeostasis. PPARα, expressed predominantly in liver, heart, and skeletal muscle, governs fatty acid oxidation and cholesterol metabolism. WY-14643 (Pirinixic Acid) is a synthetic ligand for PPARα, enabling researchers to dissect the PPAR signaling pathway in both metabolic and inflammatory contexts (Bao et al., 2025). Aliphatic α-substitution of WY-14643 further extends its activity to PPARγ, supporting investigations into dual agonist effects relevant for insulin sensitization and adipogenesis. The compound’s role in modulating TNF-α-mediated inflammation and tumor microenvironment remodeling is increasingly recognized (see advanced review).

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 binds with high specificity to the ligand-binding domain of PPARα, inducing conformational activation. Upon activation, PPARα heterodimerizes with retinoid X receptor (RXR) and binds to peroxisome proliferator response elements (PPREs) in target gene promoters. This upregulates genes involved in β-oxidation, lipid transport, and anti-inflammatory signaling.

• IC₅₀: WY-14643 exhibits an IC₅₀ of 10.11 µM for human PPARα (APExBIO A4305).
• Dual Agonism: α-Substitution on the aliphatic chain enhances both PPARα and PPARγ agonism, yielding dual modulation in the low micromolar range (site review).
• Inflammatory Pathways: By activating PPARα, WY-14643 downregulates VCAM-1 expression and reduces TNF-α-driven monocyte adhesion to endothelium, supporting its anti-inflammatory profile.

Mechanistic studies reveal that PPARα activation by WY-14643 also indirectly alters the tumor microenvironment by modulating tissue factor (TF) expression, as shown in pulmonary lymphoepithelioma-like carcinoma models (Bao et al., 2025). For a detailed mechanistic exploration, see this translational review, which this article extends by integrating inflammation and cancer microenvironment data.

Evidence & Benchmarks

• WY-14643 (Pirinixic Acid) activates PPARα with an IC₅₀ of 10.11 µM in human in vitro assays (APExBIO).
• Aliphatic α-substitution leads to balanced dual PPARα/γ agonism in the low micromolar range (site review).
• Pretreatment with 250 μM WY-14643 significantly downregulates TNF-α-induced VCAM-1 expression and reduces monocyte adhesion in endothelial cells (Bao et al., 2025).
• In high-fat-fed rats, oral WY-14643 (3 mg/kg/day, 2 weeks) lowers plasma glucose, triglycerides, leptin, muscle triglycerides, and long-chain acyl-CoAs, and reduces visceral fat and liver triglyceride content without increasing body weight (APExBIO).
• WY-14643 moderately elevates hepatic TNFα mRNA via Kupffer cells, indirectly promoting hepatocyte mitogenesis (translational review).
• Linoleic acid increases tissue factor (TF) expression via PPAR-α signaling; this pathway is targetable by PPARα agonists such as WY-14643 in tumor microenvironment models (Bao et al., 2025).

Applications, Limits & Misconceptions

WY-14643 is widely used in metabolic disorder research, cancer microenvironment modulation, and inflammation studies. Its selectivity and dual PPARα/γ agonist profile support studies in insulin sensitivity enhancement, lipid metabolism regulation, and anti-inflammatory responses. For example, it is instrumental in dissecting the role of PPAR signaling in TNF-α-mediated inflammation and in evaluating new therapeutic targets in metabolic syndrome and certain cancers. This review clarifies and updates prior site content, such as the paradigm-shifting applications article, by focusing on recent proteomics and metabolomics evidence.

Common Pitfalls or Misconceptions

• Not for Diagnostic or Clinical Use: WY-14643 is strictly for laboratory research. It is not approved for diagnostic or therapeutic use in humans (APExBIO).
• Solubility Constraints: The compound is insoluble in water but soluble in DMSO (≥16.2 mg/mL) and ethanol (≥48.8 mg/mL with ultrasound). Incorrect solvent use may yield poor experimental results.
• Short-Term Solution Stability: Solutions should be used promptly; long-term storage of solutions is not recommended due to potential degradation.
• Cell-Type Specificity: The anti-inflammatory and metabolic effects of WY-14643 may not generalize across all tissues or species; context-dependent results require validation (see further discussion).
• Dual Agonism Limits: While α-substitution enhances PPARγ activity, pure WY-14643 is primarily a PPARα agonist; dual modulation depends on structural modification.

Workflow Integration & Parameters

WY-14643 is supplied as a solid by APExBIO (SKU: A4305), to be stored at -20°C. For in vitro assays, reconstitute in DMSO or ethanol at concentrations up to 16.2 mg/mL (DMSO) or 48.8 mg/mL (ethanol with ultrasound). For in vivo use, oral administration at 3 mg/kg/day for 2 weeks is validated in high-fat-fed rat models. Pretreatment with 250 μM is effective in endothelial cell anti-inflammatory assays. Researchers should consult batch-specific certificates and conduct pilot solubility and stability checks in their target system. For detailed protocol adaptations and strategic guidance, see this strategic guidance article, which this review updates with new in vivo benchmarks.

Conclusion & Outlook

WY-14643 (Pirinixic Acid) remains a cornerstone selective PPARα agonist and research tool for metabolic, inflammatory, and tumor microenvironment studies. Its precise activity profile, dual agonism potential, and reproducible effects in validated animal and cell models ensure continued utility in preclinical research. As new omics data emerge, WY-14643’s role in dissecting PPAR signaling and its translational applications in metabolic disorder and cancer research are expected to expand. Researchers are advised to source from established suppliers such as APExBIO and adhere to recommended usage parameters for maximal reproducibility. For product details and ordering, refer to the official APExBIO WY-14643 page.